



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#20
eg. Kaye
8/15/02

In re application of Llinas-Brunet, M. et-al
Appln. No. 09/368,670
Filed: 08/05/1999
For: Hepatitis C Inhibitor Peptides
Atty. Docket No. 13/063-2-C2

Group Art Unit: 1653

Examiner: D. Lukton

Box Sequence
U. S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

RECEIVED
AUG 05 2002
TECH CENTER 1600/2900

SUBMISSION OF DUPLICATE SEQUENCE LISTING DISKETTE


Sir:

In response to the communication dated February 6, 2002, setting a one month period for response, a new computer readable form (CRF) Sequence Listing was submitted on February 12, 2002. A copy of the receipted return post card is enclosed.

Since the Applicant has received no response from the Office for that submission, a duplicate computer readable form (CRF) Sequence Listing is enclosed. Since the original submission was timely filed, we believe no fee for an extension of time is due at this time.

The Commissioner is hereby authorized to charge any other fee which may be required, and to credit any overpayment, to Deposit Account No. 02-2955. Triplicate copies of this paper are enclosed.

Respectfully submitted,



Philip I. Datlow
Attorney for Applicant(s)
Reg. No. 41,482


Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 798-4542
Date: July 30, 2002

"EXPRESS MAIL" LABEL NO.: EV 000930173 US
DEPOSIT DATE: July 30, 2002

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO:

BOX SEQUENCE
U. S. PATENT AND TRADEMARK OFFICE
P. O. BOX 2327
ARLINGTON, VA 22202

By: 
Philip I. Datlow
Reg. No. 41,482




RECEIVED

AUG 05 2002

TECH CENTER 1600/2900

13/063-2-C2 ID



APPLICANT(S): Llinas-Brunet, M. et al
SERIAL NO.: 09/368,670
FILING DATE: 08/05/99
DOCKET NO.: 13/063-2-C2
TITLE: Hepatitis C Inhibitor Peptides

IN CONNECTION WITH THE ABOVE CASE, PLEASE
DATE STAMP TO ACKNOWLEDGE RECEIPT OF THE
DOCUMENTS LISTED BELOW, AND RETURN TO
ADDRESSEE.

1. Statement Under 37 CFR § 1.821(f)
2. Sequence Listing (Diskette)

Mailed: February 12, 2002

